Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EBT Margin for 5 consecutive years, with 10.14% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 2400.0% year-over-year to 10.14%, compared with a TTM value of 12.71% through Dec 2025, up 2125.0%, and an annual FY2025 reading of 12.71%, up 2125.0% over the prior year.
  • EBT Margin was 10.14% for Q4 2025 at Kiniksa Pharmaceuticals International, down from 15.02% in the prior quarter.
  • Across five years, EBT Margin topped out at 112.22% in Q4 2023 and bottomed at 253.51% in Q3 2021.
  • Average EBT Margin over 5 years is 27.5%, with a median of 5.52% recorded in 2022.
  • The sharpest move saw EBT Margin soared 30065bps in 2022, then crashed -12607bps in 2024.
  • Year by year, EBT Margin stood at 233.66% in 2021, then soared by 98bps to 4.61% in 2022, then surged by 2533bps to 112.22% in 2023, then tumbled by -112bps to 13.86% in 2024, then skyrocketed by 173bps to 10.14% in 2025.
  • Business Quant data shows EBT Margin for KNSA at 10.14% in Q4 2025, 15.02% in Q3 2025, and 14.59% in Q2 2025.